The receptor tyrosine kinase Ron is a member of the receptor family that includes the proto-oncogene Met and the avian oncogene Sea. The interaction of Ron with its ligand, known as hepatocyte growth factor-like protein (HGFL) or macrophage stimulating protein (MSP), induces crucial cellular responses including invasive growth, proliferation, cell scattering, and branching morphogenesis. Based on the homology and functional similarities between Met and Ron it was hypothesized that Ron may be important in tumor formation and metastasis. To test this hypothesis, wildtype mouse Ron and three mutant forms of Ron containing mutations similar to those found in the Met gene in human hereditary papillary renal carcinoma (HPRC), were expressed in NIH3T3 cells. A transformed phenotype was produced in cell lines expressing either wild-type Ron or the mutated Ron proteins. Further, these cell lines displayed oncogenic potential by exhibiting increased proliferation and constitutive phosphorylation of Ron. These cell lines were also tested for the ability to form solid tumors. Cells expressing wild-type Ron and the three proteins with single amino acid substitutions were highly tumorigenic in vivo. In a model of experimental metastasis, two of the cell lines with altered Ron protein formed highly aggressive tumors in the lungs. These results suggest that Ron may be an aggressive oncogene when either overexpressed or when activated by mutation. Oncogene (2001) 20, 6142 ± 6151.
Introduction
The receptor tyrosine kinase Ron, also referred to as Stk in the mouse, is a member of the receptor tyrosine kinase family that includes the proto-oncogenes Met and the avian oncogene Sea (Iwama et al., 1994; Ronsin et al., 1993) . Ron encodes the receptor for the growth factor hepatocyte growth factor-like protein (HGFL), which is also known as macrophage stimulating protein (MSP) (Bezerra et al., 1993a; Gaudino et al., 1994; Han et al., 1991; Wang et al., 1994 Wang et al., , 1995 Yoshimura et al., 1993) . HGFL is exclusively produced in liver hepatocytes and is secreted into the bloodstream (Bezerra et al., 1993b) . Binding of HGFL to Ron has been shown to elicit complex cellular responses important for tumorigenesis and metastasis, including cell ± cell dissociation (scattering), cellular proliferation, cellular motility and morphological changes (Mera et al., 1999; Waltz et al., 1997; Wang et al., 1996a, b) . Ron expression has been detected in most tissues examined, including epithelium, liver, kidney, lung, gastrointestinal tract, brain, bone, and cells of hematopoeitic origin (Chen et al., 1998; Gaudino et al., 1994 Gaudino et al., , 1995 Kurihara et al., 1996; Quantin et al., 1995; Willett et al., 1998) .
Few studies of the expression of Ron in human tumors have been performed to date. However, there are a number of studies that suggest that Ron overexpression or constitutive activation of Ron may be important in human cancer. First, overexpression of Ron has been found in about half of the human primary breast carcinomas examined (35/74 patients) (Maggiora et al., 1998) . Expression of Ron was increased more than 20-fold in 12 of these cases. Constitutive phosphorylation of Ron was apparent in these tumors. In contrast to this overexpression in carcinomas, Ron was barely detectable in normal mammary epithelial cells, nor was the expression of Ron increased in benign breast lesions, including adenomas and papillomas. Secondly, overexpression of Ron has been found in both human hepatocellular carcinoma (HCC) and in HCC-derived cell lines . The autocrine expression of Ron and HGFL has been reported in a subset of non-small-cell lung carcinomas (Willett et al., 1998) . One splicing variant of the Ron protein was isolated from a human gastric cancer cell line and was found to be constitutively activated by dimerization; this variant produced an invasive phenotype in a cell culture assay (Collesi et al., 1996) . A second splicing variant of Ron, similar but not identical to the previously identi®ed form, was isolated from malignant human colonic tissue (Okino et al., 1999) . And ®nally, a recent report links the Ron receptor in mice to a form of viral erythroleukemia termed Friend disease (Persons et al., 1999) . The expression of a shortened transcript of the Ron receptor was found to confer susceptibility to this disease. These studies add to the growing evidence that overexpression or constitutive activation of Ron may contribute to tumorigenesis.
Point mutations in the Met gene have been identi®ed in an inherited form of kidney cancer called hereditary papillary renal carcinoma (HPRC), as well as sporadic tumors of the same type . In general, the somatic mutations were more activating than the mutations found in inherited forms of the disease. One of the point mutations found in Met in HPRC has also been identi®ed in lymph node metastases of head and neck squamous cell carcinoma (Di Renzo et al., 2000) . Several of the mutations found in HPRC were introduced into the mouse Met cDNA, and the mutations were found to be tumorigenic in vivo and transforming in vitro in NIH3T3 cells (Jeers et al., 1997) . It is also of note that two of the mutations appear in residues that, when mutated, activate the Kit and Ret receptor tyrosine kinases, which are also known to be proto-oncogenes. Analogous point mutations in Kit have been shown to induce human mast cell leukemia and human mastocytosis (Longley et al., 1996; Nagata et al., 1995; . Point mutations in the Ret receptor have been identi®ed in patients with the inherited cancer Multiple Endocrine Neoplasia type 2B (MEN) (Carlson et al., 1994; Hofstra et al., 1994) . Indeed, similar point mutations in Met, Kit, and Ret appear to cause constitutive activation of the receptor that leads to transformation in vitro and tumorigenicity in vivo. These point mutations, which appear in the tyrosine kinase catalytic domain conserved among Met, Kit, Ret, and Ron, are near the tyrosine residues which have been found to be crucial for catalytic activity (Longati et al., 1994) .
In this study, we set out to determine if overexpression of wild-type mouse Ron could induce a transformed phenotype in vitro as well as induce tumorigenesis in vivo. In addition, we have generated mutations in Ron analogous to the activating mutations found in Met, Kit, and Ret, to determine if mutations in Ron will also prove activating for transformation and tumor formation. In vitro, we have ®rst demonstrated that overexpression of wild-type Ron induces transformation. Secondly, we have shown that point mutations in Ron are activating. Thirdly, we have demonstrated that wild-type Ron as well as mutated Ron with single amino acid substitutions are tumorigenic in vivo, and that the activating point mutations are also metastatic.
Results

Point mutations in the tyrosine kinase domain of Ron
The alignment of the amino acid sequences of the kinase domains of Met, human Ron, mouse Ron, Kit and Ret, and the relative positions of the point mutations that were introduced into the mouse Ron cDNA are shown in Figure 1 . It is of note that one of these mutations, L1176V, is amino terminal to the kinase domain, while G1209H and M1231T are within the kinase domain. These three point mutations are found in homologous positions in Met found in somatic forms of HPRC. In addition, the mutation G1209H is analogous to a mutation found in Kit, and the mutation M1231T is analogous to a mutation found in Ret (Carlson et al., 1994; Hofstra et al., 1994; Longley et al., 1996; Nagata et al., 1995) .
Ron expressing cells show transformed properties
In order to investigate the ability of Ron or putative activating mutations in Ron to induce cellular transformation, stable cell lines were generated which either overexpressed wild-type Ron or the three mutated Ron proteins analogous to the mutations found in Met, Kit and Ret. The phenotypes of these cell lines are shown in Figure 2 . The cells expressing wild-type Ron protein and the three mutated proteins exhibited a transformed phenotype compared to the parental NIH3T3 cells, as judged visually by the extension of long cytoplasmic processes and the loss of contact inhibition ( Figure  2 ). The cells overexpressing wild-type Ron and the mutation M1231T exhibited the greatest phenotypic alteration. The foci forming ability of the cell lines was also evaluated. Representative plates of cells are shown in Figure 2 , and the number of foci per mg of DNA used for transformation is shown. Focus formation indicating transformation was seen in all experimental cell lines.
Selected properties of these cell lines that would be indicative of increased oncogenic potential were also examined ( Table 1 ). The proliferation rates of the cell lines were examined in the presence and absence of stimulation by HGFL. After stimulation with HGFL, the cells expressing wild-type Ron and the mutations L1176V and M1231T each showed a twofold increase in proliferation over their proliferation rates in the absence of stimulation (data not shown). However, in the absence of stimulation by growth factor, the cell lines expressing the mutated proteins exhibited signi®cantly higher proliferation rates, up to 25-fold greater than the parental NIH3T3 cells (P50.05), and cells expressing wild-type Ron showed a fourfold higher proliferation rate than the parental NIH3T3 cells. The motility response of the cell lines was also examined. The cells expressing wild-type Ron and the three mutations in Ron exhibited signi®cantly increased motility compared to NIH3T3 cells in the absence of stimulation (P50.01).
The expression of wild-type and mutated Ron was examined in two ways (Figure 3) . A Northern analysis of mRNA showed that wild-type and point mutation containing Ron transcripts were expressed at comparable levels in these cells (Figure 3a ). NIH3T3 cells have been shown to express Ron mRNA by reversetranscriptase polymerase chain reaction (RT ± PCR) (Waltz et al., 1998) , but the low level of message in this cell line was not detectable by Northern analysis.
The level of wild-type and mutant Ron protein in these cell lines was evaluated by Western analysis. Multiple evaluations were done for protein level and phosphorylation; a representative analysis is shown in Figure 3b . Ron protein from cells expressing wild-type Ron and the three mutations in Ron was found at approximately equivalent levels, but was barely detectable in untransfected NIH3T3 cells. The constitutive phosphorylation of tyrosine residues has been suggested as a mechanism for the oncogenic activation of cell lines expressing mutations in these receptors (Longati et al., 1994) . The constitutive phosphorylation and phosphorylation in response to HGFL stimulation of Ron was evaluated for each of the expressing cell lines. The relative degree of phosphorylation of Ron protein was evaluated by the ratio between the amount of Ron phosphorylation and the amount of unphosphorylated Ron determined by successively probing the same Western. Wild-type Ron and mutant Ron proteins were found to exhibit constitutive phosphorylation in these cell lines, with the three point mutations exhibiting a greater degree of constitutive phosphorylation than the wild-type receptor. After stimulation with HGFL, the phosphorylation of wildtype Ron and the M1231T mutant increased, while the G1209H and L1176V mutants did not show additional phosphorylation with stimulation. Phosphorylation of Ron in NIH3T3 cells was not detected.
Cell lines expressing Ron and mutations in Ron are tumorigenic in vivo
The tumorigenic properties of the cell lines expressing wild-type Ron and the three point mutations in Ron were evaluated by following the formation of tumors after the cells were injected in the subcutaneous dermis Figure 1 Point mutations generated in the mouse Ron cDNA. The protein sequences of the carboxy-terminal of human Met, Ron (hRon), Kit, Ret, and mouse Ron (mRon) have been aligned to show the homology between these receptors. The numbers refer to the mouse Ron amino acid sequence based on the translation of the cDNA (Waltz et al., 1998) . Identities between sequences are evidenced by dots. Asterisks indicate the catalytic tyrosine residues in the kinase domain (*). The numbered blocks show where mutations found in Met in HPRC are located, and the amino acid substitutions in these point mutations are shown below the sequences. The amino acid substitutions we have generated in constructs of mRon are shown in bold and blocked Figure 2 Transformation and focus formation of cells expressing wild-type and mutated Ron protein in NIH3T3 cells. A photograph of each of the experimental cell lines, stained with crystal violet, is shown (magni®cation 1006). A transformed phenotype was evaluated based on the loss of contact inhibition and on the presence of elongated cellular processes. The extremes in this category were the NIH3T3 cells (7) which did not exhibit these characteristics and the cells expressing wild-type Ron and M1231T (++) which exempli®ed these properties. A representative plate showing focus formation of the cell lines is also shown. The mean value from three experiments was used to calculate foci per microgram of input DNA used for transformation of nude mice ( Table 2 ). The number of mice injected which developed tumors, the average number of days to the initiation of tumors, the growth rate of these tumors, and a determination of the mitotic index of the cells within the tumors was determined for each cell line. The single tumor that arose from the injection of the control NIH3T3 cells was very slow to form and slow growing. The three cell lines expressing point mutations in Ron induced tumors with various degrees of aggressiveness. Both M1231T and G1209H induced tumors in every mouse injected, whereas L1176V induced tumors in about half of the mice. The cell lines expressing wild-type Ron also induced tumors in every mouse injected. The most aggressive mutation was M1231T; this cell line showed a signi®cantly shorter time to palpable tumor formation (P50.05) and a signi®cantly faster growth rate (P50.05) than the other cell lines. In keeping with this increased growth rate, a signi®cantly greater number of mitotic cells were seen in the tumors from cell line M1231T than in the other tumors (P50.05).
Representative sections from tumors produced by wild-type Ron and M1231T expressing cells are shown in Figure 4 . The tumors produced by subcutaneous injection of the cell lines show aggressive invasion of the underlying muscle tissue and skin, even breaking through the skin in some regions. Microcapillary formation and diusion of blood cells could also be seen in these sections.
Cell lines expressing point mutations in Ron are metastatic
The metastatic potential of cell lines expressing wildtype Ron and the three point mutations in Ron was evaluated in two ways. First, spontaneous metastasis of these cells to the lung from the subcutaneous tumors was evaluated. Secondly, a model of experimental metastasis was used to evaluate the ability of these cells to colonize and grow in the lung. The results of these evaluations are shown in Table 3 , and representative lungs as well as sections showing these tumors are shown in Figure 5 . The frequency of tumors appearing spontaneously in the lungs of mice after the growth of subcutaneous tumors was determined by a histological examination of sections of the lungs. The most aggressively growing cell line, containing mutation M1231T, showed spontaneous metastasis. Tumor formation frequency in the experimental metastasis model was evaluated by examining externally visible tumors on the lungs and histological sections of the lungs. A few cells were seen in one section of a lung from a mouse injected with the control NIH3T3 cells. However, every mouse injected with either cells expressing point mutation G1209H or M1231T showed extensive tumor formation in the lungs. Approximately 50% of the area of the lungs was seen to contain tumor cells when representative sections were examined. The tumor burden was also measured as the lung weight as a percentage of body weight. The lungs from mice injected with cells expressing G1209H and M1231T (7). Approximately equal amounts of total protein were immunoprecipitated with an antiRon antibody, probed with an anti-Ron antibody, then reprobed with an anti-phosphotyrosine antibody. Multiple analyses were evaluated for phosphorylation in the presence (+) and absence (7) of HGFL. The constitutive phosphorylation of the receptor was evaluated as the average ratio between the intensity of the phosphorylated signal of the Ron receptor to the Ron signal by Western analysis in the absence of stimulation. A negative value indicates no increase in phosphorylation was seen. The degree of phosphorylation was compared to the phosphorylation of the wild-type receptor which was set at 1 (+), with approximately twofold (++) and fourfold (+++) higher phosphorylation seen with the mutations. The phosphorylation response of the receptors after stimulation with HGFL was also evaluated on several Westerns. A negative (7) indicates no increased phosphorylation with stimulation was seen. The increases in phosphorylation were approximately twofold (++) and fourfold (+++) above unstimulated constitutive phosphorylation levels showed a signi®cantly greater weight, indicating tumor burden, than lungs from mice injected with the other cell lines (P50.05).
Discussion
Our investigations into the oncogenic properties of wild-type Ron and mutations introduced into Ron based on mutations in Met in HPRC demonstrate that overexpression of the wild-type protein, and expression of receptors with single amino acid substitutions produce highly transformed and tumorigenic cells, and that the most aggressive mutations can also metastasize to the lungs. An investigation of the cell lines showed that they display characteristics in vitro that promote tumorigenesis, such as a transformed phenotype with loss of contact inhibition, and increased proliferation and motility. The mutations that were introduced into the receptor were activating, in that they allowed the cell lines expressing the altered receptor to proliferate at a greater rate than the cells expressing wild-type receptor, and to proliferate without stimulation by exogenous growth factor in vitro. These activating mutations and the overexpression of wild-type receptor also increased the motility of the cells in the absence of HGFL stimulation. The precise positions of the point mutations that were introduced into the receptor had dramatic eects on the resulting characteristics of the cell lines expressing the mutant proteins. The mutation L1176V, amino terminal to the kinase domain, produced cells forming the greatest number of foci, and yet it produced relatively slow growing tumors in about half the mice injected. The properties of cells in vitro that allow foci to form, which may depend most on cell ± cell adhesion, may not correspond completely to the qualities necessary for tumor growth in vivo. In addition, the mutation L1176V did not form lung tumors by experimental metastasis. Experimental metastasis evaluates the ability of the cells expressing an altered protein to navigate the circulation, lodge, and proliferate in the oxygen-rich environment of the lung. It is possible to speculate that the increased cell ± cell adhesion that might promote focus formation might also interfere with the cell's ability to disperse in the circulatory system. This particular point mutation has not been tested for tumor formation in any other laboratory.
In contrast, cells expressing the protein from the mutation M1231T, within the kinase domain, produced aggressively growing tumors in every mouse injected. As well as being found in renal cancer, the identical mutation is found in Ret, where it is associated with Multiple Endocrine Neoplasia type 2B (MEN2B), a more aggressive disease than that associated with a dierent mutation in the Ret receptor (MEN2A). However, when both MEN2A and MEN2B mutations were introduced into NIH3T3 cells, the MEN2B mutants were less transformed, as judged by focus formation and phenotype (Cira®ci et al., 1997; Santoro et al., 1995) . The substitution of a serine for methionine at the same position in the Ret receptor increased constitutive phosphorylation of the receptor without producing a transformed phenotype. The authors concluded that tyrosine kinase activity did not correspond to transformation for this receptor. Instead, the mutated receptor was found to not form dimers, and was found to phosphorylate dierent substrates than the wild-type receptor, implying that the mutation operated by an alteration in signaling pathways rather than simply by an increase in phosphorylation activity leading to an increase in signaling. Interestingly, this position is occupied by threonine in a number of receptor tyrosine kinases, and by a threonine in non-receptor tyrosine kinases (Hanks et al., 1988) . Identical mutations in Met and in human Ron were also found to be highly tumorigenic (Jeers et al., 1997; Santoro et al., 1998) .
The mutation in the cell line G1209H occurs in the same position as a mutation in the Kit gene associated with mastocytosis. Interestingly, this mutation has also been shown to interfere with dimer formation in the receptor, and is also highly tumorigenic in vivo (Kitayama et al., 1995; .
Overexpression of wild-type Ron also showed constitutive phosphorylation of the receptor. This receptor activation, which increases with ligand stimulation, may drive the increased proliferation and transformed characteristics of these cell lines as well as tumor formation. The tumorigenic properties of wildtype mouse Ron are dierent from those reported for human Ron, where the expression of human Ron did not produce cell lines that displayed a transformed phenotype or formed foci (Santoro et al., 1998; Williams et al., 1999) . In one case it was reported that wild-type human Ron was not tumorigenic and did not produce metastasis in an experimental mouse model of metastasis (Santoro et al., 1998) . This contrasts sharply with our results that show that wild-type mouse Ron was transforming, produced foci, and formed subcutaneous tumors in 100% of the animals injected. However, our results are congruent with experiments investigating the oncogenic potential of wild-type human Met and wild-type murine Met, where it was found that a very low incidence of tumor formation (5%) was found when cells expressing human Met were injected subcutaneously into nude mice, although a 100% incidence of tumor formation was found when murine Met was expressed instead (Rong et al., 1992) . Tumor formation with cells expressing human Met was increased to 90% when human HGF was co-expressed with human Met. The authors concluded that Met requires a species-speci®c form of HGF for activation leading to tumor formation. In our experiments, the high concentration of circulating endogenous murine HGFL was available to activate murine Ron, and cells expressing Ron were tumorigenic. This suggests that the true oncogenic potential of Ron may not be seen outside of a species-speci®c setting. Species-speci®c factors other than the ligand HGFL may also be interacting with wild-type Ron to produce the highly tumorigenic cells lines expressing murine Ron in murine cells, in contrast to the low tumorigenic potential of the human Ron receptor in this model system. We have recently demonstrated that Ron interacts and transphosphorylates the epidermal growth factor receptor (unpublished observations). Recent reports have also shown that Ron interacts with the other heterologous receptors (Follenzi et al., 2000; Mera et al., 1999) .
In conclusion, our results suggest that Ron is a potential oncogene. The tumor formation and transformed phenotype that resulted from overexpression of wild-type Ron in NIH3T3 cells is congruent with the overexpression of Ron found in breast cancer (Maggiora et al., 1998) . The aggressively growing cell lines and tumors from cells expressing point mutations in Ron resemble point mutations in analogous regions of other tyrosine kinase receptors found in human cancers, suggesting that point mutations in Ron may also prove important in human cancer. Therefore, the further delineation of the role of Ron in human disease is warranted.
Materials and methods
Site-directed mutagenesis
The full-length cDNA coding for mouse Ron was cloned into the EcoRI site of the eukaryotic expression vector pcDNA3 (Invitrogen) (Waltz et al., 1998) . Three point mutations in this sequence were introduced into the Ron cDNA by polymerase chain reaction (PCR) based site-directed mutagenesis using a modi®ed overlap extension protocol using the appropriate oligonucleotide primers (Ho et al., 1989) . Mutants were identi®ed by PCR and veri®ed by DNA sequence analysis. The pooled cells expressing these constructs are referred to by the designation of the mutation, and the numbering of the mutation is from the translated mouse Ron cDNA (Waltz et al., 1998) . L1176V refers to the substitution of a valine for a leucine at residue 1176, G1209H refers to the substitution of a histidine for a glycine at residue 1209, and M1231T refers to the substitution of a threonine for a methionine at residue 1231.
Cell culture, transfection, and RNA analysis
The three point mutation-containing constructs and a construct for wild-type mouse Ron were introduced as stable transfectants into NIH3T3 cells (ATCC). Transfections were performed using the calcium-phosphate precipitation method as previously described (Waltz et al., 1996) . Cells were maintained in Dulbecco's Modi®ed Eagle's Medium (DMEM, Gibco) supplemented with 10% fetal calf serum, 2 mM 1-glutamine, and 50 ug/ml gentamicin (Gibco). Transfected cells were selected by the addition of 800 ug/ml G-418 (Fisher) to this media, and maintained with a concentration of 200 ug/ml G-418. Cells expressing each of the mutants or wild-type Ron were pooled and used in the indicated experiments. To determine the level of Ron over-expression, mRNA was isolated by standard protocols and Northern analysis was performed. Hybridizations were performed with the full-length mouse Ron cDNA and with sequences homologous to GADPH.
Cell morphology and focus formation
Phenotypic transformation was judged visually based on cell morphology, contact inhibited cell growth, and the presence of elongated cytoplasmic extensions. The individual cell lines were given a ranking based on these parameters. Foci were counted on con¯uent plates in triplicate after 15 days of growth in reduced-serum media (5% FBS). The focusforming abilities of the individual cell lines were then ranked.
Proliferation assays
The parental NIH3T3 cells and each experimental cell line were seeded in six wells each in a 96-well culture plate at a concentration of 5610 3 cells/well in 100 ml of complete media, for the assay of stimulated cell proliferation and unstimulated cell proliferation in triplicate. After 48 h, the media was removed and the cells starved in 200 ml of media containing 0.5% serum. After 48 h, recombinant HGFL protein at 400 ng/ml (R&D) was added to three wells. Twenty-four hours after stimulation, 10 ml of 5-bromo-2'-deoxyuridine (BrdU) was added for 16 h. The amount of BrdU incorporation was determined using a colorimetric ELISA-based BrdU labeling and detection kit (Roche Biotechnology) according to the manufacturer's instructions.
Transwell motility assay
The parental NIH3T3 cells and each experimental cell line were starved for 24 h in media containing minimum serum prior to the migration assay (0.5% FBS added to maintain cell viability). Polyethylene terephthalate (PET) membranes (8 mm pore size) were placed in 24-well culture dishes. Each cell line was plated on the membrane at 10 5 cells in 200 ml of serum-free media. Each treatment was done in triplicate. One ml of media containing recombinant HGFL protein at 400 ng/ml (R&D) or control media (0.5% FBS) was added to the culture dish. After 24 h incubation, the cells on the upper level of the membrane were removed by swabbing, and the cells that had migrated through the membrane were ®xed and stained with 0.1 M crystal violet in 200 mM boric acid. The crystal violet was destained in acetic acid solution, and the optical density of the resulting solutions read at 590 nm. The optical density is proportional to the number of cells absorbing the dye. The cell motility is reported as the ratio between the mean optical densities from the expressing cell lines compared to that from the parental NIH3T3 cells.
Immunoprecipitation and Western analysis
Recombinant human HGFL expressed in CHO cells was used to stimulate the Ron receptor in vitro as previously described (Waltz et al., 1997) . The conditioned media containing recombinant HGFL from these cells, and conditioned media from CHO cells, was treated with 100 nM porcine kallikrein and 500 nM soybean trypsin inhibitor (STI) (Sigma) to activate the recombinant protein.
The conditioned media was diluted with serum-free media containing 1 nM sodium orthovanadate to obtain a HGFL concentration of 400 ng/ml. The experimental cells were stimulated with HGFL for 15 min at 378C.
The parental NIH3T3 cells and each experimental cell line were grown to approximately 70 ± 80% con¯uency in 150 mm plates. The plates were placed on ice, then the cells were scraped from the plates and combined before lysis. Cells were lysed on ice for 20 min in 1 ml of buer containing 50 mM Tris-Cl (pH=8.0), 150 mM NaCl, 1% Triton X-100, and 1 nM sodium orthovanadate, supplemented with the protease inhibitors aprotinin, leupeptin, and pepstatin at 0.001 mg/ml, and NaF and phenylmethylsulfonyl¯uoride (PMSF) at 1 mM (Sigma). Cell debris was pelleted by centrifugation at 15 000 g for 15 min at 48C. The cell lysate was pre-cleared with 100 ml of a 50% slurry of Protein-G Agarose (Upstate Biotechnology) for 10 min at 48C. The total protein content of the lysate was determined using a standard Bradford assay (reagent, BioRad). The solubilized proteins were immunoprecipitated with 80 ml of Protein-G Agarose and 6.25 ug of Ron-a monoclonal antibody (Transduction Laboratories) overnight at 48C. The immunoprecipitated proteins were resolved on a 7.5% Tris-Glycine-polyacrylamide gel (PAGEr GOLD, Fisher Scienti®c) and blotted on PVDF membrane (Millipore). The membranes were probed with anti-Ron b-chain monoclonal antibody (R&D), stripped, and reprobed with an anti-phosphotyrosine monoclonal antibody, clone 4G10 (Upstate Biotechnology). The detection system used secondary antibodies conjugated to alkaline phosphatase (Vector Labs) and the enhanced chemi¯uorescence reagent (ECF) (Amersham). Westerns were scanned on a STORM imaging system (Molecular Dynamics) and quantitatively analysed using ImageQuant software (Molecular Dynamics).
Tumor formation and spontaneous metastasis
Pooled cells from each expressing cell line were injected subcutaneously into weanling female nude mice (BALB/c, Taconic) at 10 6 cells/injection. Following the injection, the mice were examined 2 ± 3 times per week. The date at which tumors began to form, and the growth of the tumors was monitored by palpation. The tumors that resulted from this subcutaneous injection were excised when the longest side reached approximately 12 mm. The tumor tissue was formalin ®xed, paran embedded, and sections taken. The sections were stained with hemotoxylin/eosin and examined by light microscopy. The number of mitotic cells in 1 mm 2 was determined by counting mitotic cells in three areas of the tumor, delineated by a graticule.
When the mice appeared to be in distress or at the end of the experiment at 20 weeks, they were sacri®ced, and the lungs excised. The average growth rate of the tumors was calculated as tumor volume in cubic mm per day of growth. The volume of a tumor was calculated from its dimensions (length6width 2 )/2, assuming a hemiellipsoid shape (Geran et al., 1972) , and the days of growth were determined from the date of tumor removal and the date of tumor initiation. The lung tissue was formalin ®xed and paran embedded. Five parallel sections were taken, separated by 150 mm. The sections were stained with hemotoxylin/eosin for examination by light microscopy.
Experimental metastasis
The experimental pulmonary metastasis model experiments were performed with the cell lines previously described. The cells were injected at a concentration of 10 6 cells/injection into the tail vein of female weanling nude mice (BALB/c, Charles River). Following injection, the mice were examined 2 ± 3 times per week. The general health of the mice was monitored. The mice were sacri®ced at 12+1 week post injection. The tumor burden was calculated as the lung weight as a percentage of body weight. The lung tissue was formalin ®xed and paran embedded for histological examination as previously described.
Statistical analysis
Statistical comparisons were performed using two-way analysis of variance (ANOVA). This software package StatView (SAS Institute) was utilized for this analysis.
